XBIO · XBRL financial data

Xenetic Biosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	437	1,161	1,707	2,540	2,500	2,976
Research and development	1,731	3,163	4,771	3,495	3,288	3,065
General and administrative	3,400	3,744	3,654	3,561	3,416	2,746
Total operating expenses	14,375	6,907	8,425	7,056	6,705	5,811
Operating income (loss)	(13,938)	(5,747)	(6,718)	(4,516)	(4,204)	(2,835)
Other income (expense)	(0)	1	(2)	25	(6)	6
Income tax expense (benefit)	(2,919)	0	0	0	0	0
Net income (loss)	(10,893)	(5,645)	(6,552)	(4,135)	(3,960)	(2,681)
Earnings per share, basic USD per share	—	(0.55)	(0.46)	(2.71)	(2.57)	(1.58)
Earnings per share, diluted USD per share	—	(0.55)	(0.46)	(2.71)	(2.57)	(1.58)
Weighted average shares, basic thousands of shares	—	10,279	14,224	1,528	1,541	1,702
Weighted average shares, diluted thousands of shares	—	10,279	14,224	1,528	1,541	1,702

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	11,528	18,244	13,097	8,983	6,166	7,884
Prepaid and other current assets	842	479	556	604	422	166
Total current assets	12,370	18,723	13,653	9,587	6,588	8,050
Property and equipment, net	0	0	0	—	—	—
Right-of-use asset	35	—	—	—	—	—
Goodwill	0	—	—	—	—	—
Total assets	13,179	19,815	14,720	10,605	6,901	8,364
Accounts payable	327	362	287	241	284	258
Accrued liabilities	574	1,032	786	569	611	710
Total current liabilities	937	1,421	1,073	810	894	968
Lease liability, non-current	27	—	—	—	—	—
Total liabilities	964	1,421	1,073	810	894	968
Accumulated deficit	(176,902)	(182,547)	(189,100)	(193,234)	(197,194)	(199,875)
Total stockholders' equity	12,216	18,394	13,647	9,796	6,007	7,396
Total liabilities and equity	13,179	19,815	14,720	10,605	6,901	8,364
Common shares outstanding (cover page) thousands of shares	8,747	13,441	15,167	1,541	1,542	2,291

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(10,893)	(5,645)	(6,552)	(4,135)	(3,960)	(2,681)
Stock-based compensation	469	410	511	283	172	65
Net cash from operating activities	(4,267)	(4,738)	(4,647)	(4,114)	(2,817)	(2,287)
Net cash from investing activities	0	0	(500)	0	—	—
Proceeds from issuing common stock	5,427	11,451	0	—	0	4,005
Proceeds from issuing equity	0	—	—	—	—	—
Net cash from financing activities	5,427	11,455	0	—	0	4,005

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Skinvisible	4	5	2.2*	5.4M	—	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Silo Pharma	3,277	0*	(782)*	1.6M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Astria Therapeutics	96,280	706	(32,295)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Adia Nutrition	128	485	(109)*	94.4M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.